title: Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
abstract: OBJECTIVE
  To assess the effect on sexual function of alfuzosin 10 mg once daily, a uroselective alpha(1)-blocker, in men with lower urinary tract symptoms (LUTS) suggestive of bladder outlet obstruction.
  
  
  METHODS
  In all, 3076 men (mean age 65.9 years) were treated for 1 year with alfuzosin 10 mg in 'real life' practice. They were asked to complete the International Prostatic Symptom Score (IPSS), its appended eighth question (bother score) and the Danish Prostatic Symptom Score questionnaire for sexual dysfunction (DAN-PSSsex). The results were analysed at the endpoint in the intent-to-treat population.
  
  
  RESULTS
  At baseline, 2434 (79.1%) men were sexually active and answered correctly at least one item of the DAN-PSSsex. Sexual dysfunction was highly prevalent (reduced stiffness of erection, 65.3%; reduced volume of ejaculate, 63.2%; pain/discomfort on ejaculation, 20.2%), and was strongly related to the severity of LUTS and impairment of quality of life. At the endpoint, alfuzosin significantly improved the total IPSS (-6.1, - 32%) and bother score (-1.4, - 33.2%, both P < 0.001) over baseline. In those men with sexual dysfunction there were significant improvements in weighted scores related to reduced rigidity of erection (-0.5), reduced amount of ejaculate (-0.4) and pain/discomfort on ejaculation (-1.2, all P < 0.001) over baseline. The perceived improvements were more marked in men with severe LUTS or a severe bother score at baseline.
  
  
  CONCLUSIONS
  Sexual dysfunction is highly prevalent in men with LUTS and related to the baseline IPSS and bother score. Alfuzosin 10 mg once daily for 1 year is effective in improving LUTS and quality of life, and is well tolerated. It may even improve sexual function in those men with concomitant erectile and/or ejaculatory dysfunction.
authors.affiliation: Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands. R.J.A.vanMoorselaar@chir.azu.nl
authors.forename: R Jeroen A
authors.initials: RJ
authors.lastname: van Moorselaar
authors.forename: Rudolf
authors.initials: R
authors.lastname: Hartung
authors.forename: Mark
authors.initials: M
authors.lastname: Emberton
authors.forename: Niels
authors.initials: N
authors.lastname: Harving
authors.forename: Haim
authors.initials: H
authors.lastname: Matzkin
authors.forename: Mostafa
authors.initials: M
authors.lastname: Elhilali
authors.forename: Antonio
authors.initials: A
authors.lastname: Alcaraz
authors.forename: Guy
authors.initials: G
authors.lastname: Vallancien
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D004542:Ejaculation / Q000187:drug effects; D006801:Humans; D008297:Male; D010146:Pain / Q000209:etiology; D010410:Penile Erection / Q000187:drug effects; D011788:Quality of Life; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D016896:Treatment Outcome; D001748:Urinary Bladder Neck Obstruction / Q000150:complications*; D014555:Urination Disorders / Q000209:etiology*
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin